A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

Phase 1 Completed 32 enrolled Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the multiple dose pharmacokinetics (PK) of three gefapixant (AF-219) formulations; to assess the effect of Omeprazole on the multiple dose PK of three gefapixant formulations; and, to assess the safety and tolerability of gefapixant.

Timeline

Start: 2016-05-16
Primary completion: 2016-06-15
Completion: 2016-06-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefapixant	Small molecule	15 mg	Oral
Subject	Gefapixant	Small molecule	30 mg	Oral
Subject	Omeprazole	Other / unclassified	20 mg	Oral
Subject	Omeprazole	Other / unclassified	40 mg	Oral

Indications

No indication recorded.